By developing a two-site tumor system model, a study found that liver metastasis can inhibit systemic anti-tumor immune response, and proposed that CTLA-4 inhibitors or enhancer of zeste homolog 2 (EZH2) inhibitors combined with PD-1 inhibitors can restore systemic anti-tumor immune activity (52). Here, EZH2 is linked to neoplasm.